Takeda submits new drug application for type 2 diabetes drug in Japan
Furiex Pharmaceuticals, under its agreement with Takeda, is eligible to receive royalties and sales-based milestones if trelagliptin succinate is approved and marketed in Japan. Takeda Pharmaceutical has submitted
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.